AstraZeneca hikes earnings forecast after surging cancer drug sales

Anglo-Swedish drugmaker AstraZeneca on Thursday upped its earnings forecasts for the year as surging sales of cancer medicines offset plummeting sales of COVID vaccines.

The uptick in AstraZeneca’s revenues was largely driven by a 17% increase in sales of cancer drugs at constant exchange rates, to $4.66 billion, on the back of 53% higher sales of its cancer immunotherapy drug Imfinzi. Excluding lower sales of COVID vaccines across the globe, AstraZeneca’s sales increased in all regions worldwide, apart from China, as the firm showed particularly strong growth in emerging markets.

مصر أحدث الأخبار, مصر عناوين

Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.

Geopolitical clash could still spark market incident, Deutsche Bank CEO warnsLouis Goss is a MarketWatch reporter based in London.
مصدر: MarketWatch - 🏆 3. / 97 اقرأ أكثر »

Uber notches earnings beat but comes up short on the top lineEmily Bary is a MarketWatch news editor based in New York.
مصدر: MarketWatch - 🏆 3. / 97 اقرأ أكثر »